Navigation Links
TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
Date:5/12/2008

PHILADELPHIA, May 12 /PRNewswire-USNewswire/ -- GlaxoSmithKline (GSK), in collaboration with the Breast International Group (BIG), a leading academic breast cancer research network, and one of its member groups, the Spanish Breast Cancer Cooperative Group (SOLTI), today announced the start of a global Phase III study that will examine the role of TYKERB(R) in the treatment of early breast cancer. Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization) will evaluate and compare the rate at which cancer cells disappear in the breast following treatment with TYKERB and/or trastuzumab before surgery in women with early-stage HER2-positive breast cancer. This type of treatment is referred to as neo-adjuvant therapy. TYKERB is an investigational drug and has not yet been approved for this indication.

"The evolution seen in breast cancer care has been tremendous in the last few decades," said Dr. Jose Baselga, Co-Chair on Neo-ALTTO and Chair of the SOLTI Group, Spain. "Surgery, in the form of a radical mastectomy of the breast, was traditionally the first line treatment offered to patients with little or no improvement in overall survival. Now we have a range of sophisticated targeted treatments that can significantly delay disease progression and increase survival. Through trials such as Neo-ALTTO, oncologists may be better able to optimize the use of these agents."

One in four women diagnosed with early breast cancer have tumors that are HER2-positive.(1) It is well recognized that these women have a higher risk of their cancer returning - either at the location of the original tumor or when the cancer spreads to other organs - even after receiving additional therapies.(1)

"The launch of Neo-ALTTO is extremely exciting as this study will help physicians answer important clinical questions relating to the neoadjuvant treatment regimen of HER2-positive breast cancer," said Dr. Martine Piccart, Chairperson of the Breast
'/>"/>

SOURCE GlaxoSmithKline; Breast International Group; SpanishBreast Cancer
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
2. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
3. Hospital Launches Landmark Emergency Medicine Project
4. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
5. Viatronix V3D-Colon Utilized in Another Landmark Study
6. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
7. Starting Flu Vaccination in August Could Help Protect Nearly 11 Million More Children During Scheduled Doctors Visits
8. Data Show Preoperative Assessment of Breast Cancer Patients Enables Early Diagnosis, Successful Treatment of Lymphedema
9. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
10. Gene Therapy Provides Vision to People who Were Nearly Blind
11. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Roughly three-quarters ... very confident substituting an interchangeable biosimilar for its ... the same nonproprietary name, according to a survey ... (AMCP,s) Journal of Managed Care & Specialty ... 25 percent of pharmacists would feel as confident ...
(Date:2/27/2015)... Feb. 27, 2015  Pomerantz LLP is investigating claims ... or the "Company") (NASDAQ: VTAE ).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On February 27, 2015, the Company ...
(Date:2/27/2015)... February 27, 2015 ... dell,innovativo sistema di monitoraggio dell,infarto congestizio (CHF - ...     Vectorious ... nuovo sistema per il monitoraggio cardiaco destinato a ... oggi di aver concluso una raccolta di finanziamenti ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... FREMONT, Calif., Nov. 19 Quark Pharmaceuticals, Inc., the leader ... its siRNA R&D platform based programs have met clinical development ... a new IND opened for ocular neuroprotection drug candidate QPI ... has completed enrollment in a Phase 2 study of PF-4523655 ...
... Nov. 19 Radiall and Integral Process will collaborate in ... agreement to confirm this new alliance. , Radiall has a ... time, the company has established relationships with major players in ... , Integral Process is a key supplier of interconnect ...
Cached Medicine Technology:Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 2Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 3Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials 4Radiall and Integral Process Sign Agreement 2
(Date:3/1/2015)... Indiana (PRWEB) March 01, 2015 ... statewide Network Service Provider, announces NewWays Networking, LLC ... “By working with IFN, NewWays is well ... meet client’s demand for Internet bandwidth in rural ... , According to Cory Childs IFN Enterprise ...
(Date:2/28/2015)... Malaysia (PRWEB) February 28, 2015 The ... all across Malaysia into one platform and gears towards ... , A series of group talks in smaller ... like Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, ... and raise awareness of Malaysian youths. , ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... February 28, 2015 Vancouver personal injury lawyers ... claims are affected by time limits. They stated that in ... person’s claim or even nullify it. Many a time, delays ... a client’s rights under BC law. As a result, experts ... by accidents should consult a personal injury lawyer in order ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be ... Materials Show, an annual, premier sustainable building event in ... top manufacturers of the latest building products, services and ... and manufactured by Pioneer Millworks from their Oregon and ... restaurants, hotels, retailers, and corporate offices. Nichibi Global ...
Breaking Medicine News(10 mins):Health News:NewWays Networking Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... data from previously completed withdrawal to monotherapy studies for ... studies, obviating the need for placebo/pseudo-placebo trials to demonstrate ... this study are now available online in Epilepsia ... the International League Against Epilepsy. According to a ...
... is available in French . Montreal, ... Heart Institute (MHI) has shown unexpectedly that living with children ... with 756 participants and led by Dr. Simon L. Bacon, ... the study assessed the impact of social networks on exercise, ...
... lives of infants and children with developmental disabilities will ... Developmental Disabilities Research Center (WUIDDRC). The center, established ... National Institutes of Health (NIH), will focus on research ... emphasis will be placed on clinical and translational research ...
... 2010 - Janice Morse, RN, PhD, FAAN, a professor ... inducted into the newly created Sigma Theta Tau International ... researchers who have achieved long-term, broad national and/or international ... research has impacted the profession and the people it ...
... the skin cancer melanoma appear different in Florida than ,from ... non-Hispanic black women but lower rates among Hispanic women, according ... of Dermatology, one of the JAMA/Archives journals. "In ... than that of any other cancer," the authors write as ...
... , MONDAY, July 19 (HealthDay News) -- Children conceived using ... than do children who were conceived naturally, new research shows. ... increased by 42 percent for Swedish youngsters conceived with IVF, ... "We found a roughly 50 percent increased risk for cancer ...
Cached Medicine News:Health News:FDA accepts historical controls for epilepsy monotherapy studies 2Health News:FDA accepts historical controls for epilepsy monotherapy studies 3Health News:Concordia researcher leads study that finds kids reduce physical activity for heart patients 2Health News:Developmental disabilities center established at Washington University 2Health News:U of U's Janice Morse inducted into International Nurse Researcher Hall of Fame 2Health News:Melanoma rates among minorities in Florida differ from national trends 2Health News:Study Suggests Higher Cancer Rate Among IVF Babies 2Health News:Study Suggests Higher Cancer Rate Among IVF Babies 3
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
... S System offers unparalleld speed, providing ... minute requiring only 10 ul of ... provide more comprehensive patient care by ... The CoaguChek S System is easy-to-use, ...
Medicine Products: